Optical biosensors are a technology that holds promise to address numerous applications in medical research and diagnostics. Affinity biosensors based on surface plasmons (sometimes called plasmonic biosensors) represent the most advanced optical label-free biosensor technology. They have been widely used to investigate biomolecular interactions related to the onset or progression of diseases and to detect and quantify disease biomarkers.
In this lecture, we discuss the main challenges in developing plasmonic biosensors for medical diagnostics and present a few selected advances in plasmonic biosensor research that aim to address some of these challenges. These include advances in plasmonic nanostructures and instrumentation, microfluidic systems, functional materials, and detection assays. We also discuss two applications of plasmonic biosensors related to the diagnosis of Myelodysplastic syndromes (MDS - a group of hematological malignancies with a risk of progression into acute myeloid leukemia). First, we present a new extremely sensitive assay for detecting MDS-related microribonucleic acids (miRNAs) and demonstrate that it enables the detection of miRNAs in blood plasma with a limit of detection < 350 aM. Second, we present a biosensor-based approach to the monitoring of progression of MDS based on the analysis of the interaction between an array of proteins and blood plasma samples and show that this interaction approach allows for discrimination among different stages of MDS and healthy controls.
|